Management strategies for systemic lupus erythematosus using kinase inhibitors

Abstract

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease that is undergoing a revolution in its treatment paradigm. Receptor kinases including Janus (JAK) kinases, Bruton's tyrosine kinase (BTK), and spleen tyrosine kinase (SYK) are essential for signalling of many cytokines and receptors on immune cells. Suppression of these kinases changes the activation state of target cells, leading to inhibition of cytokine actions and effects such as autoantibody secretion. Therefore, therapeutic kinase inhibitors hold potential as treatments for SLE, but their efficacy and safety remain to be determined. Tyrosine kinase 2 and JAK inhibitors such as deucravacitinib and upadacitinib respectively have shown positive results in phase 2 trials, while further research into the JAK inhibitor baricitinib and BTK and SYK inhibitors has been less encouraging. This review summarises the current state of research on the use of kinase inhibitors in SLE.

Keywords

Systemic lupus erythematosus / SLE / receptor kinase inhibitors

References

[1] Tian J,Yao X,Lu Q.Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study.Ann Rheum Dis2023;82:351-6 PMCID:PMC9933169

[2] Morand EF,Tanaka Y.Trial of anifrolumab in active systemic lupus erythematosus.N Engl J Med2020;382:211-21

[3] Moulton VR,Meidan E,Mizui M.Pathogenesis of human systemic lupus erythematosus: a cellular perspective.Trends Mol Med2017;23:615-35 PMCID:PMC5650102

[4] Crow MK.Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets.Ann Rheum Dis2023;82:999-1014

[5] Dubey AK,Dubey S,Sharma KK.Belimumab: first targeted biological treatment for systemic lupus erythematosus.J Pharmacol Pharmacother2011;2:317-9 PMCID:PMC3198539

[6] Thomson RJ,Ronquillo Y. Tyrosine kinase inhibitors. StatPearls. Treasure Island (FL) Ineligible Companies, 2024. Available from: https://clinicaltrials.gov/study/NCT03288324 [Last accessed on 19 Jan 2026].

[7] Hu X,Fu M,Wang W.The JAK/STAT signaling pathway: from bench to clinic.Signal Transduct Target Ther2021;6:402 PMCID:PMC8617206

[8] Cleary JM.Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.Curr Oncol Rep2010;12:87-94 PMCID:PMC3883721

[9] Favalli EG,Caporali R.Biologics or janus kinase inhibitors in rheumatoid arthritis patients who are insufficient responders to conventional anti-rheumatic drugs.Drugs2024;84:877-94 PMCID:PMC11343917

[10] Tanaka Y,O'Shea JJ.Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.Nat Rev Rheumatol2022;18:133-45 PMCID:PMC8730299

[11] Alunno A,Fanouriakis A.Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent.Cells2019;8:898 PMCID:PMC6721755

[12] Jamilloux Y,Vuitton L,Kerever S.JAK inhibitors for the treatment of autoimmune and inflammatory diseases.Autoimmun Rev2019;18:102390

[13] Xue C,Gu X.Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.Signal Transduct Target Ther2023;8:204 PMCID:PMC10196327

[14] Ripoll È,Draibe Bordignon J.JAK3-STAT pathway blocking benefits in experimental lupus nephritis.Arthritis Res Ther2016;18:134 PMCID:PMC4898357

[15] Lu LD,Wallace NH.Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.J Immunol2011;187:3840-53

[16] Twomey RE,Westmoreland SV.Therapeutic JAK1 inhibition reverses lupus nephritis in a mouse model and demonstrates transcriptional changes consistent with human disease.ACR Open Rheumatol2024;6:900-11 PMCID:PMC11638135

[17] Dong G,Fan H,Sun L.STS-1 promotes IFN-α induced autophagy by activating the JAK1-STAT1 signaling pathway in B cells.Eur J Immunol2015;45:2377-88

[18] Furumoto Y,Blanco L.Tofacitinib ameliorates murine lupus and its associated vascular dysfunction.Arthritis Rheumatol2017;69:148-60 PMCID:PMC5195893

[19] Li X,Yang D.A case report of systemic lupus erythematosus complicating interstitial lung disease and thickened pericardium treated with tofacitinib.Medicine2024;103:e39129

[20] Chen YL,Huang Q,Hong XP.Case report: reversal of long-standing refractory diffuse non-scarring alopecia due to systemic lupus erythematosus following treatment with tofacitinib.Front Immunol2021;12:654376 PMCID:PMC8080875

[21] Hasni SA,Davis M.Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.Nat Commun2021;12:3391 PMCID:PMC8185103

[22] Alsukait S,Rosmarin D.Open-label phase 2 pilot study of oral tofacitinib in adult subjects with discoid lupus erythematosus (DLE).J Drugs Dermatol2023;22:425-7

[23] Clinicaltrials.gov. Open-label study of tofacitinib for moderate to severe skin involvement in young adults with lupus. 2024. Available from: https://clinicaltrials.gov/study/NCT03288324 [Last accessed on 28 Nov 2025].

[24] Nakayamada S.Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?.Expert Opin Investig Drugs2023;32:901-8

[25] Wallace DJ,Tanaka Y.Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.Lancet2018;392:222-31

[26] Dörner T,Petri MA.Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.Lupus Sci Med2020;7:e000424 PMCID:PMC7549481

[27] Morand EF,Petri M.Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).Lancet2023;401:1001-10

[28] Petri M,Dörner T.Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).Lancet2023;401:1011-9

[29] Yin J,Wang C.Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: Pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials.PLoS One2025;20:e0320179 PMCID:PMC12043178

[30] Connelly K,Kandane-Rathnayake R.Clinician-reported outcome measures in lupus trials: a problem worth solving.Lancet Rheumatol2021;3:e595-603

[31] Askanase AD,Meier O.Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials.Lupus Sci Med2025;12:e001483 PMCID:PMC12090859

[32] Clinicaltrials.gov. A dose-ranging study to evaluate efficacy and safety of PF-06700841 in systemic lupus erythematosus (SLE). 2024. Available from: https://clinicaltrials.gov/study/NCT03845517 [Last accessed on 28 Nov 2025].

[33] Morand E,Merrill JT.Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial.Arthritis Rheumatol2023;75:242-52 PMCID:PMC10100399

[34] Werth VP,Robern M.Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.Rheumatology2022;61:2413-23 PMCID:PMC9157055

[35] Baker M,Genovese M.Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.RMD Open2020;6:e001490 PMCID:PMC7780527

[36] Merrill JT,D'Cruz D.Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial.Arthritis Rheumatol2024;76:1518-29

[37] Kahl L,Layton M.Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.Lupus2016;25:1420-30

[38] Chan ES,Ali J.Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model.J Invest Dermatol2015;135:2338-9

[39] Klaeschen AS,Brossart P,Wenzel J.JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.Exp Dermatol2017;26:728-30

[40] Park JJ,Vesely MD.Treatment of cutaneous lupus with topical ruxolitinib cream.JAAD Case Rep2022;28:133-5 PMCID:PMC9494033

[41] Jung JI,Kim MH.Successful treatment of hemophagocytic lymphohistiocytosis in a patient with systemic lupus erythematosus with ruxolitinib: a case report.J Rheum Dis2024;31:125-9 PMCID:PMC10973350

[42] Ringheim GE,Oberoi K.Bruton's tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures.Front Immunol2021;12:662223 PMCID:PMC8595937

[43] Ding Q,Feng Y,Zhang T.Bruton's tyrosine kinase: a promising target for treating systemic lupus erythematosus.Int Immunopharmacol2024;142:113040

[44] Wallace DJ,Pisetsky DS.Efficacy and safety of the bruton's tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial.ACR Open Rheumatol2023;5:38-48 PMCID:PMC9837396

[45] Tanaka Y,Yamaoka K,Yasuda S.Rituximab in the real-world treatment of lupus nephritis: a retrospective cohort study in Japan.Mod Rheumatol2023;33:145-53

[46] Liao HT,Tsai CY,Yu CL.Bruton's tyrosine kinase in systemic lupus erythematosus.Joint Bone Spine2020;87:670-2

[47] Kim YY,Jang SY.HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.Arthritis Res Ther2017;19:211 PMCID:PMC5615432

[48] Li R,Liu S,Xie C.LB0005 orelabrutinib, an irreversible inhibitor of bruton's tyrosine kinase (BTK), for the treatment of systemic lupus erythematosus (SLE): results of a randomized, double-blinder, placebo-controlled, phase IB/IIA dose-finding study.Ann Rheum Dis2022;81:210

[49] Isenberg D,Jones NS.Efficacy, safety, and pharmacodynamic effects of the bruton's tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial.Arthritis Rheumatol2021;73:1835-46

[50] Mina-Osorio P,Keirstead N.Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.Arthritis Rheum2013;65:2380-91

[51] Chalmers SA,Doerner J.Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.Arthritis Res Ther2018;20:10 PMCID:PMC5785891

[52] Weißenberg SY,Schrezenmeier E.Identification and characterization of post-activated B cells in systemic autoimmune diseases.Front Immunol2019;10:2136 PMCID:PMC6768969

[53] Mok CC.Targeted small molecules for systemic lupus erythematosus: drugs in the pipeline.Drugs2023;83:479-96 PMCID:PMC10042116

[54] Mócsai A,Tybulewicz VL.The SYK tyrosine kinase: a crucial player in diverse biological functions.Nat Rev Immunol2010;10:387-402 PMCID:PMC4782221

[55] Cooper N,Hill QA,Markovtsov V.Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.Platelets2023;34:2131751

[56] Grammatikos AP,Devlin A,Tsokos GC.Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling.PLoS One2013;8:e74550 PMCID:PMC3754955

[57] Pohlmeyer CW,Han P.Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.BMC Rheumatol2021;5:15 PMCID:PMC8008554

[58] Tanaka Y,Iwata S.Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.Rheumatology2021;60:2884-95

[59] Bussel J,Grossbard E.Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.Am J Hematol2018;93:921-30 PMCID:PMC6055608

[60] Deng GM,Bahjat FR,Tsokos GC.Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.Arthritis Rheum2010;62:2086-92 PMCID:PMC2902591

[61] Cho S,Yoon T,Youn J.A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models.Clin Exp Immunol2023;211:31-45 PMCID:PMC9993459

[62] Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.Signal Transduct Target Ther2023;8:262 PMCID:PMC10326056

[63] Rambhatla A,De Paredes JG,Thakur M.Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.J Assist Reprod Genet2021;38:1897-908 PMCID:PMC8417172

[64] Rosario R,Anderson RA.Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies.Reprod Fertil2022;3:R147-62 PMCID:PMC9346327

[65] Dou X,Huang X.Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.Oncologist2019;24:e1141-7 PMCID:PMC6853119

[66] Hoisnard L,Dray-Spira R,Zureik M.Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.Ann Rheum Dis2023;82:182-8

[67] Ytterberg SR,Connell CA.Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.N Engl J Med2022;386:1766-8

[68] Adas MA,Cook E,Galloway JB.The infection risks of JAK inhibition.Expert Rev Clin Immunol2022;18:253-61 PMCID:PMC8935945

[69] Zhang F,Bass D.A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.Ann Rheum Dis2018;77:355-63 PMCID:PMC5867402

[70] Bass AR,Akl EA.2022 American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases.Arthritis Care Res2023;75:449-64 PMCID:PMC10291822

[71] Awan FT,Alfraih F.International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.Blood Adv2022;6:5516-25 PMCID:PMC9631706

[72] Weinblatt ME,Genovese MC,Grossbard EB.An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.N Engl J Med2010;363:1303-12

[73] He Y,Zhang GG.Targeting PI3K/Akt signal transduction for cancer therapy.Signal Transduct Target Ther2021;6:425 PMCID:PMC8677728

[74] Hawkins PT.PI3K signalling in inflammation.Biochim Biophys Acta2015;1851:882-97

[75] Omori SA,Anzelon-Mills A.Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling.Immunity2006;25:545-57

[76] Bacalao MA.Recent advances in lupus B cell biology: PI3K, IFNγ, and chromatin.Front Immunol2020;11:615673 PMCID:PMC7841329

[77] O'Neill SK,Gauld SB.Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.Immunity2011;35:746-56 PMCID:PMC3232011

[78] Wu XN,Niu JW.Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus.Sci Transl Med2014;6:246ra99

[79] Olayinka-Adefemi F,Marshall AJ.Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus.Front Immunol2023;14:1115244 PMCID:PMC10206234

[80] Gopal AK,de Vos S.PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.N Engl J Med2014;370:1008-18

[81] Gribben JG,Jacobs RW.Umbralisib plus ublituximab (U2) Is superior to obinutuzumab plus chlorambucil (O+Chl) in patients with treatment naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): results from the phase 3 Unity-CLL study.Blood2020;136:37-9

[82] Lui SL,Chan KW.Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.Nephrol Dial Transplant2008;23:2768-76

[83] Yap DY,Tang CS.Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience.Nephrology2012;17:676-80

[84] Lai ZW,Winans T.Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.Lancet2018;391:1186-96 PMCID:PMC5891154

[85] Michailidou D,Askanase AD.The role of mTOR signaling pathway in systemic lupus erythematosus and systemic vasculitis.Autoimmun Rev2025;24:103910

[86] Brightbill HD,Blaquiere N.NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.Nat Commun2018;9:179

[87] Scherlinger M,Pan W.CaMK4 controls follicular helper T cell expansion and function during normal and autoimmune T-dependent B cell responses.Nat Commun2024;15:840 PMCID:PMC10825135